Mushrooms and Stroke Recovery
22-44% infarct reduction
A 2025 systematic review confirmed erinacine A from Lion's Mane mycelium reduced brain infarct size by 22 to 44 percent in the gold-standard stroke model across preclinical studies.
Spangenberg et al., Frontiers in Pharmacology, 2025
6 species
mushroom species with stroke-relevant preclinical evidence
0 human trials
testing mushrooms specifically for stroke recovery in patients
5 mechanisms
Cordyceps pathways against cerebrovascular ischemic injury identified in 2024 review (Li et al.)
Spangenberg et al., Frontiers in Pharmacology, 2025
View as image ↗In 2025, Spangenberg and colleagues published a systematic review analyzing every preclinical study on erinacines, the small compounds found exclusively in Lion's Mane mushroom mycelium. Their finding for mushrooms and stroke recovery: in the gold-standard ischemic stroke model, where the middle cerebral artery is temporarily blocked to simulate stroke, erinacine A reduced brain infarct size by 22 to 44 percent.[1] The research does not begin and end there.
Six mushroom species have accumulated preclinical evidence for stroke neuroprotection, each through a different mechanism: Lion's Mane via compounds that trigger the brain's antioxidant defense system, Cordyceps via a peptide that suppresses the post-stroke inflammatory cascade, Reishi via hippocampal protection and dual cell death pathway suppression, Poria cocos via a triterpenoid that activates a pro-survival signaling pathway, Antrodia camphorata via embolic stroke protection without the hemorrhage risk of standard drugs, and Sparassis crispa via a vascular mechanism that actually delayed stroke incidence in stroke-prone rats.
This is a preclinical body of evidence. No human clinical trial has tested any of these species specifically in stroke recovery. But the breadth of mechanisms across species is unusual, and some of the findings, particularly the hemorrhagic safety data from Antrodia and the human cohort data linking ergothioneine to cerebrovascular disease risk, offer angles that go beyond typical preclinical interest. This article is part of the broader picture of how mushrooms interact with brain health and cognitive aging.
Key Takeaways
- Spangenberg et al. (2025) systematic review confirmed erinacine A and C from Lion's Mane reduce neuroinflammation, induce Nrf2 (the cell's antioxidant defense coordinator), and improve behavioral outcomes including 22–44% infarct reduction in MCAO stroke models[1]
- Wang et al. (2012) tested Cordymin, a peptide purified from Cordyceps sinensis, in focal cerebral ischemia rats and found significant suppression of IL-1beta, TNF-alpha, and neutrophil infiltration alongside improved neurobehavioral function[3]
- Pang et al. (2020) found pachymic acid from Poria cocos reduced cerebral ischemia/reperfusion injury in rats by activating the PI3K/Akt pro-survival signaling pathway in neurons[8]
- Lee et al. (2014) showed Antrodia camphorata extract reduced embolic stroke damage in rats without increasing the hemorrhagic transformation risk that limits standard thrombolytics[9]
- Wu et al. (2021) found in a human cohort study that low plasma ergothioneine levels were significantly associated with both neurodegeneration and cerebrovascular disease markers; mushrooms are the primary dietary ergothioneine source[12]
- Yu et al. (2024) found psilocybin improved locomotor recovery and upregulated synaptic density markers while reducing microglial overactivation in stroke-model rats via a mechanism confirmed to involve BDNF, the brain's main repair signal[13]
What Stroke Does to the Brain (and Why This Points to Specific Mushroom Properties)
A stroke occurs when blood flow to part of the brain is cut off, either by a clot (ischemic stroke, about 87% of cases) or a burst blood vessel (hemorrhagic stroke). Within minutes of blood flow loss, neurons in the core of the affected region begin to die from lack of oxygen and glucose. But the injury does not stop when blood flow is restored.
The return of blood flow, called reperfusion, triggers a second wave of damage. Oxygen flooding back into oxygen-starved tissue generates damaging molecules called reactive oxygen species. The brain's immune cells, called microglia, activate to clean up debris but can overactivate and attack healthy tissue in the process. Inflammatory signaling proteins flood the area and drive a cascade of secondary injury that expands the damage beyond the original blockage zone.
This two-phase injury structure tells us what mushroom compounds need to do to be relevant to stroke: they need to either reduce the initial cell death (neuroprotection), dampen the secondary inflammatory cascade (anti-inflammatory/anti-apoptotic), or support the repair and rewiring process that follows (neuroplasticity). The six species covered here address all three phases, through different mechanisms.
For a deeper look at the anti-inflammatory mechanisms specifically, the anti-inflammatory mushroom stroke article covers the microglia and cytokine angle in detail. For the neuroplasticity and brain rewiring evidence, the post-stroke neuroplasticity article covers synaptogenesis, axonal sprouting, and remyelination data separately.
Lion's Mane: 22-44% Infarct Reduction in a Gold-Standard Stroke Model
The standard preclinical model for ischemic stroke research is called the MCAO model: the middle cerebral artery is temporarily blocked using a fine filament, depriving a specific brain region of blood flow for a set time. After the blockage is removed, researchers measure infarct volume (the volume of dead brain tissue), neurological deficits, and behavioral function. It is the closest approximation to human ischemic stroke available in animal research.
Spangenberg and colleagues (2025) analyzed all preclinical studies on erinacines, the diterpenoid compounds found in Lion's Mane mycelium, across neurodegeneration models including MCAO stroke.[1] The review confirmed: erinacine A and C reduce neuroinflammation, activate a protective protein called Nrf2 that coordinates the cell's antioxidant response, suppress the apoptotic signals that push neurons toward death, and enhance neurogenesis (the production of new neurons). Across MCAO stroke studies, infarct reduction ranged from 22 to 44 percent.
Li and colleagues (2018) had reviewed the same literature more specifically for stroke, Alzheimer's, and Parkinson's models, confirming that erinacine-enriched mycelium exerted antiapoptotic effects, promoted neurogenesis, and produced cognitive and behavioral improvements in ischemic stroke animal models.[2]
The mechanism behind these effects is dual: erinacines stimulate nerve growth factor (NGF), a protein that supports neuron survival and the growth of new connections, and they trigger the Nrf2 antioxidant pathway, which reduces the reactive oxygen species damage that drives secondary injury. These are separate pathways operating in parallel, which may explain why the effect size in MCAO models is consistently above 20 percent reduction.
One important caveat specific to Lion's Mane: erinacines have been confirmed to cross the blood-brain barrier in preclinical animal studies, but no human pharmacokinetic study has confirmed what concentrations actually reach brain tissue in people. The 22-44% infarct reduction data comes from animal studies where compounds were administered directly at specific doses. For the mechanistic details of BBB penetration, the blood-brain barrier protection article covers what is and is not established.
Cordyceps: Five Mechanisms from One Species in Stroke Models
Cordyceps sinensis has more stroke-specific research than any other mushroom species besides Lion's Mane, and it operates through a distinct mechanism: cellular energy preservation rather than antioxidant defense.
Wang and colleagues (2012) isolated Cordymin, a specific peptide from Cordyceps sinensis, and tested it in MCAO-induced focal cerebral ischemia in rats.[3] The result: Cordymin significantly reduced the inflammatory proteins IL-1beta and TNF-alpha, decreased a complement protein (C3) involved in the inflammatory cascade, suppressed neutrophil infiltration into the brain, and improved neurobehavioral function. Critically, it was the isolated peptide being tested, not a whole extract, making this one of the more mechanistically specific mushroom stroke studies.
Bai and colleagues (2020) took a different angle: they examined how Cordyceps sinensis extract protects against cerebral ischemia by targeting mitochondria.[4] Mitochondria are the energy producers of cells, and during ischemia they fail rapidly as oxygen and glucose disappear. Cordyceps sinensis extract preserved mitochondrial respiratory chain function and blocked the mitochondrial apoptotic cascade, the sequence of signals that commits ischemic cells to die. Protecting mitochondria is relevant to the acute injury phase because it extends the window during which neurons can survive reduced blood flow.
Li and colleagues (2024) published a comprehensive review that synthesized the Cordyceps literature into five mechanisms against cerebrovascular ischemic injury: improving blood perfusion, scavenging reactive oxygen species, suppressing neuroinflammation, preventing cellular apoptosis, and promoting tissue regeneration.[5] All five address different stages of the two-phase injury process described above. No other mushroom species has a comparable multi-mechanism synthesis in the stroke-specific literature. For the detailed compound-by-compound breakdown across species, the cerebral ischemia preclinical evidence article covers each mechanism in depth.
Reishi: Hippocampal Protection and a Special Case for Diabetic Patients
Reishi (Ganoderma lucidum) shows two distinct lines of stroke-relevant evidence, one for general stroke protection and one specifically relevant to diabetic patients, whose brains are particularly vulnerable to ischemic injury.
Zhang and colleagues (2014) found that seven days of Ganoderma lucidum pretreatment significantly reduced hippocampal neuronal loss after cerebral ischemia/reperfusion injury in rats.[6] The hippocampus is the brain region most vulnerable to ischemic damage and most responsible for memory and spatial navigation. In addition to reducing neuronal loss, Reishi pretreatment decreased a marker of oxidative damage (MDA), reduced inflammatory proteins TNF-alpha and IL-8, increased the activity of an antioxidant enzyme (SOD), and improved learning and memory performance in behavioral tests.
Xuan and colleagues (2015) addressed a specific and underreported angle: stroke in patients with type 2 diabetes.[7] Diabetes roughly doubles stroke risk and worsens outcomes when stroke occurs. In a diabetic mouse model with hypoxia/ischemia, a water-soluble Ganoderma lucidum mycelium extract protected the brain by blocking both of the two main mechanisms of ischemic cell death: apoptosis (programmed cell death triggered by internal signals) and necroptosis (a form of programmed necrosis triggered by external inflammatory signals). Blocking both pathways simultaneously is mechanistically more complete than blocking either alone. The diabetic stroke model result is particularly relevant because diabetic patients represent a high-proportion subgroup of actual stroke patients, and the available treatments are the same as for non-diabetic patients.
Three Species You May Not Know: Poria, Antrodia, and Sparassis
Beyond the well-known mushroom genera, three less-familiar species have produced notable stroke research.
Poria cocos (Fu Ling) is a parasitic fungus that grows on the roots of pine trees, used for centuries in traditional Chinese medicine. Pang and colleagues (2020) found that pachymic acid, a compound derived from Poria cocos, significantly reduced cerebral ischemia/reperfusion injury in rats by activating a cellular pro-survival pathway called PI3K/Akt.[8] The PI3K/Akt pathway is a central cell survival signal: when activated, it suppresses several apoptotic proteins and promotes cell repair. Activating it during reperfusion injury helps neurons survive the oxidative burst that follows blood flow restoration.
Antrodia camphorata is a rare fungus that grows exclusively on the inner heartwood of the Taiwanese red cypress. Lee and colleagues (2014) tested its extract in an embolic stroke model in rats, where blood clots are injected to simulate the most common type of human ischemic stroke.[9] The extract significantly reduced brain damage while critically not increasing hemorrhagic transformation risk. Hemorrhagic transformation (where ischemic brain tissue begins to bleed after blood flow is restored) is the main safety concern with standard thrombolytic drugs and limits who can receive them. An extract that reduces damage without increasing bleeding risk has a different safety profile from current pharmacological options.
Wang and colleagues (2019) extended the Antrodia findings: an isolated sterol compound from Antrodia camphorata reduced ischemic stroke injury by simultaneously suppressing NF-kB and caspase-3 (the inflammatory and apoptotic cascades) while activating the Akt/GSK3/beta-catenin pathway, which promotes the generation of new neurons after injury.[10] This dual action in the acute injury phase (suppressing cell death) and recovery phase (promoting neurogenesis) in a single compound is notable.
Sparassis crispa (cauliflower mushroom) is the least-studied of the three, but the most striking in terms of stroke-prevention rather than stroke-recovery evidence. Yoshitomi and colleagues (2011) administered Sparassis crispa to stroke-prone spontaneously hypertensive rats (SHRSP), a breed that develops strokes spontaneously due to high blood pressure.[11] The result: Sparassis crispa significantly delayed stroke incidence and death, decreased blood pressure, and increased cerebral blood flow. The mechanism: increased Akt-dependent phosphorylation of eNOS, the enzyme that produces nitric oxide (a molecule that relaxes blood vessel walls and improves blood flow). This is a vascular mechanism that prevents the ischemic event from occurring in the first place, not just limiting damage after it happens.
Ergothioneine: The Human Cohort Data That Connects Mushrooms to Cerebrovascular Risk
Unlike the animal model data above, ergothioneine research includes a human cohort study linking mushroom consumption directly to cerebrovascular disease risk.
Ergothioneine is an amino acid found in high concentrations in mushrooms and almost nowhere else in the diet. The body has a dedicated transporter protein (called ETT or SLC22A4) that actively transports ergothioneine into tissues, including the brain. It accumulates in neurons and brain cells, where it acts as an antioxidant.
Wu and colleagues (2021) measured plasma ergothioneine levels in 299 participants with dementia and found that low ergothioneine levels were significantly associated with both markers of neurodegeneration AND markers of cerebrovascular disease.[12] This is a human cohort study, not an animal model, making it a different class of evidence from the rest of this article. It does not prove that eating mushrooms prevents stroke. It establishes that ergothioneine status is associated with cerebrovascular disease risk in humans, which is the first step toward understanding whether dietary mushroom intake might influence that risk over time.
The ergothioneine connection is distinct from all the other mushroom compounds discussed here: it is not a bioactive extract administered in animal experiments but a dietary compound that can be obtained through regular mushroom consumption. For the detailed ergothioneine brain research, the dedicated ergothioneine brain health article covers the full evidence base for this compound.
Psilocybin and Post-Stroke Brain Rewiring: A Different Mushroom, a Different Mechanism
Psilocybin mushrooms are biologically distinct from medicinal mushrooms: they are not the same species as Lion's Mane, Cordyceps, or Reishi. But because psilocybin is derived from a fungus, any comprehensive treatment of mushrooms and stroke recovery should include the 2024 stroke data.
Yu and colleagues (2024) tested psilocybin in a rat stroke model.[13] The findings had two distinct components. In pre-treatment (psilocybin given before stroke induction), it reduced brain infarction and neurological deficits. In post-treatment (psilocybin given after stroke), it improved locomotor recovery, upregulated two markers of healthy synaptic structure: MAP2 (a protein found in neuron body structure) and synaptophysin (a protein at synaptic connections, used as a measure of synaptic density). It also reduced the overactivation of microglia (the brain's immune cells) measured by IBA1.
The mechanism was confirmed using an inhibitor: blocking BDNF signaling (brain-derived neurotrophic factor, the brain's primary repair and growth signal) abolished psilocybin's protective effects, confirming that BDNF upregulation is how psilocybin acts in this model.
This 2024 finding has received no consumer coverage. The psilocybin-BDNF mechanism in post-stroke recovery is a different angle from the compounds found in functional medicinal mushrooms, but it points toward the importance of synaptogenic and neurotrophic signaling in stroke recovery, pathways that other mushroom compounds also influence through different routes. For readers interested in the broader TBI comparison, the traumatic brain injury research covers how similar neuroplasticity mechanisms apply in non-vascular brain injury.
No Human Stroke Trials Exist: The Honest Assessment
Phan and colleagues (2015) reviewed the neuroprotective potential of culinary-medicinal mushrooms for neurodegenerative conditions broadly, confirming the diversity of mechanisms across species, including NGF stimulation, antioxidant pathways, and anti-neuroinflammatory signaling.[14] That breadth of mechanistic coverage across species is what makes the stroke research landscape unusual compared to single-compound pharmaceutical development.
But no compound from any of these mushroom species has been tested in a human stroke clinical trial. Zero. Not in the acute phase. Not in the recovery phase. Not even in a small safety-dose pilot study.
This is not a reason to dismiss the preclinical evidence. It is a reason to be precise about what the evidence shows. What it shows: in carefully controlled animal models, multiple mushroom-derived compounds reduce brain infarct size, suppress post-stroke neuroinflammation, protect specific brain regions from ischemic death, and in some cases promote recovery signals. What it does not show: that taking mushroom supplements after a stroke improves outcomes in humans.
The compounds that perform well in animal stroke models face the same translation challenges as every other preclinical neuroprotectant: bioavailability in humans is different from in rats, dosing is different, the timing of injury is different (human strokes are not always caught in the window studied in MCAO models), and stroke patients often have comorbidities that change how the brain responds to compounds. For older adults looking to support brain health broadly while this research matures, the brain health in older adults overview covers what the current evidence supports as reasonable dietary approaches.
The Bottom Line
Six mushroom species have preclinical evidence for stroke neuroprotection through distinct mechanisms: Lion's Mane (erinacine A, 22-44% infarct reduction in MCAO models, 2025 systematic review), Cordyceps (Cordymin peptide + mitochondrial protection + five documented mechanisms), Reishi (hippocampal protection, dual apoptosis/necroptosis suppression in diabetic stroke models), Poria cocos (pachymic acid, PI3K/Akt), Antrodia camphorata (embolic stroke protection without hemorrhagic risk), and Sparassis crispa (delayed stroke incidence via vascular eNOS mechanism in stroke-prone rats). Ergothioneine deficiency is associated with cerebrovascular disease risk in a human cohort study. No human clinical trials have tested any species in stroke patients.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.
- 9. Source details for this reference are not yet available.
- 10. Source details for this reference are not yet available.
- 11. Source details for this reference are not yet available.
- 12. Source details for this reference are not yet available.
- 13. Source details for this reference are not yet available.
- 14. Source details for this reference are not yet available.